Relay Therapeutics (NASDAQ:RLAY) Price Target Raised to $17.00
Relay Therapeutics (NASDAQ:RLAY – Free Report) had its price target boosted by Barclays from $14.00 to $17.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock. Several other equities research analysts also recently commented on RLAY. JMP Securities decreased their target price on shares of […]
More Stories
Blueprint Medicines (NASDAQ:BPMC) Shares Gap Up – Time to Buy?
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) gapped up before the market opened on Monday . The...
Invesco Trust for Investment Grade New York Municipals (VTN) To Go Ex-Dividend on January 17th
Invesco Trust for Investment Grade New York Municipals (NYSE:VTN – Get Free Report) declared a monthly dividend on Thursday, January...
WD-40 (WDFC) To Go Ex-Dividend on January 17th
WD-40 (NASDAQ:WDFC – Get Free Report) declared a quarterly dividend on Wednesday, December 11th,RTT News reports. Shareholders of record on...
Meridian Financial Partners LLC Takes $267,000 Position in Vanguard ESG US Stock ETF (BATS:ESGV)
Meridian Financial Partners LLC bought a new position in Vanguard ESG US Stock ETF (BATS:ESGV – Free Report) in the...
Acropolis Investment Management LLC Has $2.44 Million Stock Holdings in iShares Russell 1000 ETF (NYSEARCA:IWB)
Acropolis Investment Management LLC boosted its position in shares of iShares Russell 1000 ETF (NYSEARCA:IWB – Free Report) by 2.8%...
Acropolis Investment Management LLC Acquires 1,411 Shares of iShares ESG Aware MSCI EAFE ETF (NASDAQ:ESGD)
Acropolis Investment Management LLC increased its stake in iShares ESG Aware MSCI EAFE ETF (NASDAQ:ESGD – Free Report) by 12.8%...